Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Damage-associated molecular patterns (DAMPs) and self-antigens are endogenous molecules that serve as signals of cellular stress, damage, or non-programmed cell death, triggering innate and adaptive immune responses (Roh & Sohn, 2018). DAMPs, such as high mobility group box 1 (HMGB1), S100 proteins, and heat shock proteins, are released into the extracellular space where they interact with pattern recognition receptors (PRRs) like Toll-like receptors (TLRs) and the receptor for advanced glycation end-products (RAGE) (Gong et al., 2020). This interaction initiates sterile inflammation, which is crucial for tissue repair but can lead to chronic inflammatory diseases, sepsis, and cancer when dysregulated (Zindel & Kubes, 2020). Self-antigens are typically normal cellular components that become targets of the adaptive immune system in autoimmune disorders, such as myelin basic protein in multiple sclerosis or insulin in type 1 diabetes (Janeway et al., 2001). Therapeutic interventions targeting this category include monoclonal antibodies designed to neutralize specific DAMPs or small molecules that block their receptors to dampen pathological inflammation (Venereau et al., 2015). However, because many DAMPs have essential intracellular functions, therapeutic targeting requires precision to avoid interfering with normal physiological processes and wound healing (Harris et al., 2012).
Neutralization of endogenous ligands or blockade of pattern recognition receptors (PRRs) to inhibit downstream inflammatory signaling pathways (Venereau et al., 2015).
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Damage-associated molecular pattern and self-antigen (DAMP).